A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma - Zhang, Yang; Luo, Fan; Ma, Yu-Xiang; Liu, Qian-Wen; Yang, Yun-Peng; Fang, Wen-Feng; Huang, Yan; Zhou, Ting; Li, Jin; Pan, Hong-Ming; Yang, Lei; Qin, Shu-Kui; et al. (The oncologist (Dayton, Ohio), 2022)
Keywords: Antimitotic agents; Antineoplastic agents; Cancer; Clinical Trial Results; Development and progression; Drug therapy; Genetic aspects; Humans; Metastasis; Naphthalenes; Nasopharyngeal cancer; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Neoplasms - drug therapy; Nasopharyngeal Neoplasms - pathology; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Oncology, Experimental; Patient outcomes; Pharmaceutical research; Quinolines - therapeutic use; China; anti-angiogenic therapy; kinase inhibitor; phase I trial; nasopharyngeal carcinoma; AL3810